Safety of stavudine in the treatment of HIV infection with a special focus on resource-limited settings

Expert Opinion on Drug Safety

Volumn 7, Issue 3, 2008, Pages 283-293

  Makinson, Alain ^a   Le Moing, Vincent ^a,b   Kouanfack, Charles ^c   Laurent, Christian ^b   Delaporte, Eric ^a,b  

^a MONTPELLIER UNIVERSITY HOSPITAL   (France)

^b UNIV MONTPELLIER   (France)

^c YAOUNDÉ CENTRAL HOSPITAL   (Cameroon)

Author keywords

Antiretroviral therapy; D4T; HIV; Resource limited settings; Safety; Stavudine; Toxicity

Indexed keywords

ABACAVIR; ABACAVIR PLUS LAMIVUDINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; DIDANOSINE; DIDANOSINE PLUS HYDROXYCARBAMIDE PLUS STAVUDINE; DIDANOSINE PLUS STAVUDINE; EFAVIRENZ; EMTRICITABINE; GENERIC DRUG; INDINAVIR; INDINAVIR PLUS LAMIVUDINE PLUS STAVUDINE; INDINAVIR PLUS LAMIVUDINE PLUS ZIDOVUDINE; ISONIAZID; LAMIVUDINE; LAMIVUDINE PLUS NEVIRAPINE PLUS STAVUDINE; LAMIVUDINE PLUS TENOFOVIR; LAMIVUDINE PLUS ZIDOVUDINE; NEVIRAPINE; NUCLEOSIDE ANALOG; PROTEINASE INHIBITOR; PYRIDOXINE; RITONAVIR; RITONAVIR PLUS STAVUDINE; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; TENOFOVIR; UNINDEXED DRUG; VINCA ALKALOID; ZALCITABINE; ZIDOVUDINE;

BODY FAT; BOTTUCK ATROPHY; BUTTOCK ATROPHY; CLINICAL TRIAL; COHORT ANALYSIS; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG ELIMINATION; DRUG HALF LIFE; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DYSLIPIDEMIA; EXERCISE; FACIAL ATROPHY; FATTY LIVER; HEPATITIS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERCHOLESTEROLEMIA; HYPERINSULINEMIA; HYPERLACTATEMIA; INSULIN RESISTANCE; LACTIC ACIDOSIS; LEG ATROPHY; LIPOATROPHY; LIVER TOXICITY; LOW DRUG DOSE; METABOLIC DISORDER; MICROVESICULAR STEATOSIS; MITOCHONDRIAL TOXICITY; NEUROTOXICITY; PANCREAS DISEASE; PANCREAS TOXICITY; PANCREATITIS; PATHOPHYSIOLOGY; PATIENT COMPLIANCE; PERIPHERAL NEUROPATHY; PHARMACODYNAMICS; RECOMMENDED DRUG DOSE; REVIEW; SEX DIFFERENCE; SIDE EFFECT; TUBERCULOSIS; UNSPECIFIED SIDE EFFECT; VASCULAR DISEASE; VENOMEGALY; VIROLOGY; CHEMICALLY INDUCED DISORDER; FEMALE; HEALTH CARE PLANNING; HIV ASSOCIATED LIPODYSTROPHY; MALE;

ACIDOSIS, LACTIC; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; FEMALE; HEALTH RESOURCES; HIV INFECTIONS; HIV-ASSOCIATED LIPODYSTROPHY SYNDROME; HUMANS; MALE; PERIPHERAL NERVOUS SYSTEM DISEASES; REVERSE TRANSCRIPTASE INHIBITORS; SEX FACTORS; STAVUDINE;

EID: 44949106506     PISSN: 14740338     EISSN: None     Source Type: Journal    
DOI: 10.1517/14740338.7.3.283     Document Type: Review

References (89)

1. Palella FJ Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Out-patient Study Investigators. N Engl J Med 1998;338:853-60
2. Molina JM, Cheuc G, Ferchal F, et al. Results of the ALBI trial: a randomized comparison of stavudine/didanosine, zidovudine/lamivudine and alternating treatment in antiretroviral-naive patients. Antivir Ther 1999;4(Suppl 3):71-4
3. van Leth F, Phanuphak P, Ruxrungtham K, et al. Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomized open-label trial, the 2NN Study. Lancet 2004;363:1253-63
4. Gallant JE, Staszewski S, Pozniak AL, et al. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA 2004;292:191-201
5. Walmsley S, Bernstein B, King M, et al. Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection. N Engl J Med 2002;346:2039-46
6. van Leeuwen R, Katlama C, Murphy RL, et al. A randomized trial to study first-line combination therapy with or without a protease inhibitor in HIV-1-infected patients. AIDS 2003;17:987-99
7. Murphy RL, Sanne I, Calm P, et al. Dose-ranging, randomized, clinical trial of atazanavir with lamivudine and stavudine in antiretroviral-naive subjects: 48-week results. AIDS 2003;17:2603-14
8. Shlay JC, Visnegarwala F, Bartsch G, et al. Body composition and metabolic changes in antiretroviral-naive patients randomized to didanosine and stavudine vs abacavir and lamivudine. J Acquir Immune Delfic Syndr 2005;38:147-55
9. Podzamczer D, Ferrer E, Sanchez P, et al. Less lipoatrophy and better lipid profile with abacavir as compared to stavudine: 96-week results of a randomized study. J Acquir Immune Defic Syndr 2007;44:139-47
10. Gazzard B, Bernard AJ, Boffito M, et al. British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy (2006). HIV Med 2006;7:487-503
11. Guidelines for the use of antiretroviral agents in HIV-1 infected adults and adolescents. United States Departement of Health and Human Services (DHHS), 2007. Available from: www.aidsinfo.nih.gov/ContentFiles/ AdultandAdolescentGL.pdf [Last accessed 11 January 2008]
12. Idigbe EO, Adewole TA, Eisen G, et al. Management of HIV-1 infection with a combination of nevirapine, stavudine, and lamivudine: a preliminary report on the Nigerian antiretroviral program. J Acquir Immune Defic Syndr 2005;40:65-9
13. Kumarasamy N, Vallabhaneni S, Cecelia AJ, et al. Reasons for modification of generic highly active antiretroviral therapeutic regimens among patients in southern India. J Acquir Immune Defic Syndr 2006;41:53-8
14. Wester CW, Kim S, Bussmann H, et al. Initial response to highly active antiretroviral therapy in HIV-1C-infected adults in a public sector treatment programme in Botswana. J Acquir Immune Defic Syndr 2005;40:336-43
15. Zhou J, Paton NI, Ditangco R, et al. Experience with the use of a first-line regimen of stavudine, lamivudine and nevirapine in patients in the TREAT Asia HIV Observational Database. HIV Med 2007;8:8-16
16. Pujari SN, Patel AK, Naik E, et al. Effectiveness of generic fixed-dose combinations of highly active antiretroviral therapy for treatment of HIV infection in India. J Acquir Immune Defic Syndr 2004;37:1566-9
17. Laurent C, Kouanfack C, Koulla-Shiro S, et al. Effectiveness and safety of a generic fixed-dose combination of nevirapine, stavudine, and lamivudine in HIV-1-infected adults in Cameroon: open-label multi-centre trial. Lancet 2004;364:29-34
18. Antiretroviral therapy for HIV infection in adults and adolescents in resource-limited settings: towards universal access. Recommandations for a public health approach. 2006 revision. Geneva, Switzerland: World Health Organization, 2006. Available from: www.who.int/hiv/pub/ guidelines/artadultguidelines.pdf [Last accessed 11 January 2008]
19. Crane H, Grunfeld C, Harrington R, Kitahata M. Lipoatrophy (LA) lipohypertrophy (LH) are independently associated with depression and health-related quality of life (HRQOL); lipoatrophy is associated with adherence [abstract P-20]. Antivir Ther 2007;12(Suppl 2):L32
20. Isel C, Ehresmann C, Walter P, et al. The emergence of different resistance mechanisms toward nucleoside inhibitors is explained by the properties of the wild type HIV-1 reverse transcriptase. J Biol Chem 2001;276:48725-32
21. Piliero PJ. Pharmacokinetic properties of nucleoside/nucleotide reverse transcriptase inhibitors. J Acquir Immune Defic Syndr 2004;37(Suppl 1):S2-12
22. Havlir DV, Tierney C, Friedland GH, et al. In vivo antagonism with zidovudine plus stavudine combination therapy. J Infect Dis 2000;182:321-5
23. Hosseinipour MC, Corbett AH, Kanyama C, et al. Pharmacokinetic comparison of generic and trade formulations of lamivudine, stavudine and nevirapine in HIV-infected Malawian adults. AIDS 2007;21:59-64
24. McComsey G, Lonergan JT. Mitochondrial dysfunction: patient monitoring and toxicity management. J Acquir Immune Defic Syndr 2004;37(Suppl 1):S30-5
25. Carr A, Cooper DA. Adverse effects of antiretroviral therapy. Lancet 2000;356:1423-30
26. Birkus G, Hitchcock MJ, Cihlar T. Assessment of mitochondrial toxicity in human cells treated with tenofovir: comparison with other nucleoside reverse transcriptase inhibitors. Antimicrob Agents Chemother 2002;46:716-23
27. McComsey GA, Paulsen DM, Lonergan JT, et al. Improvements in lipoatrophy, mitochondrial DNA levels and fat apoptosis after replacing stavudine with abacavir or zidovudine. AIDS 2005;19:15-23
28. Ogedegbe AE, Thomas DL, Diehl AM. Hyperlactataemia syndromes associated with HIV therapy. Lancet Infect Dis 2003;3:329-37
29. Cherry CL, McArthur JC, Hoy JF, Wesselingh SL. Nucleoside analogues and neuropathy in the era of HAART. J Clin Virol 2003;26:195-207
30. Subbaraman R, Chaguturu SK, Mayer KH, et al. Adverse effects of highly active antiretroviral therapy in developing countries. Clin Infect Dis 2007;45:1093-101
31. Lichtenstein KA, Armon C, Baron A, et al. Modification of the incidence of drug-associated symmetrical peripheral neuropathy by host and disease factors in the HIV out-patient study cohort. Clin Infect Dis 2005;40:148-57
32. Forna F, Liechty CA, Solberg P, et al. Clinical toxicity of highly active antiretroviral therapy in a home-based AIDS care programme in rural Uganda. J Acquir Immune Defic Syndr 2007;44:456-62
33. Hawkins C, Achenbach C, Fryda W, et al. Antiretroviral durability and tolerability in HIV-infected adults living in urban Kenya. J Acquir Immune Defic Syndr 2007;45:304-10
34. Jacobson DL, Knox T, Spiegelman D, et al. Prevalence of, evolution of, and risk factors for fat atrophy and fat deposition in a cohort of HIV-infected men and women. Clin Infect Dis 2005;40:1837-45
35. Saint-Marc T, Partisani M, Poizot-Martin I, et al. A syndrome of peripheral fat wasting (lipodystrophy) in patients receiving long-term nucleoside analogue therapy. AIDS 1999;13:1659-67
36. Calmy A, Hirschel B, Cooper DA, Carr A. Clinical update: adverse effects of antiretroviral therapy. Lancet 2007;370:12-4
37. Bernasconi E, Boubaker K, Junghans C, et al. Abnormalities of body fat distribution in HIV-infected persons treated with antiretroviral drugs: the Swiss HIV Cohort Study. J Acquir Immune Defic Syndr 2002;31:50-5
38. Chene G, Amellal B, Pedrono G, et al. Changes in the peripheral blood mtDNA levels in naive patients treated by different nucleoside reverse transcriptase inhibitor combinations and their association with subsequent lipodystrophy. AIDS Res Hum Retroviruses 2007;23:54-61
39. Joly V, Flandre P, Meiffredy V, et al. Increased risk of lipoatrophy under stavudine in HIV-1-infected patients: results of a substudy from a comparative trial. AIDS 2002;16:2447-54
40. Paton NI, Earnest A, Ng YM, et al. Lipodystrophy in a cohort of human immunodeficiency virus-infected Asian patients: prevalence, associated factors, and psychological impact. Clin Infect Dis 2002;35:1244-9
41. Duran S, Saves M, Spire B, et al. Failure to maintain long-term adherence to highly active antiretroviral therapy: the role of lipodystrophy. AIDS 2001;15:2441-4
42. Pujari SN, Dravid A, Naik E, et al. Lipodystrophy and dyslipidemia among patients taking first-line, World Health Organization-recommended highly active antiretroviral therapy regimens in Western India. J Acquir Immune Defic Syndr 2005;39:199-202
43. van Griensven J, De Naeyer L, Mushi T, et al. High prevalence of lipoatrophy among patients on stavudine-containing first-line antiretroviral therapy regimens in Rwanda. Trans R Soc Trop Med Hyg 2007;101:793-8
44. Boubaker K, Flepp M, Sudre P, et al. Hyperlactatemia and antiretroviral therapy: the Swiss HIV Cohort Study. Clin Infect Dis 2001;33:1931-7
45. John M, Moore CB, James IR, et al. Chronic hyperlactatemia in HIV-infected patients taking antiretroviral therapy. AIDS 2001;15:717-23
46. Currier JS. Sex differences in antiretroviral therapy toxicity: lactic acidosis, stavudine, and women. Clin Infect Dis 2007;45:261-2
47. Bolhaar MG, Karstaedt AS. A high incidence of lactic acidosis and symptomatic hyperlactatemia in women receiving highly active antiretroviral therapy in Soweto, South Africa. Clin Infect Dis 2007;45:254-60
48. Wester CW, Okezie OA, Thomas AM, et al. Higher-than-expected rates of lactic acidosis among highly active antiretroviral therapy-treated women in Botswana: preliminary results from a large randomized clinical trial. J Acquir Immune Defic Syndr 2007;46:318-22
49. Songa PM, Castelnuovo B, Mugasha EB, et al. Symptomatic hyperlactatemia associated with nucleoside analogue reverse-transcriptase inhibitor use in HIV-infected patients: a report of 24 cases in a resource-limited setting (Uganda). Clin Infect Dis 2007;45:514-7
50. Ivers LC, Mukherjee JS. Point of care testing for antiretroviral therapy-related lactic acidosis in resource-poor settings. AIDS 2006;20:779-80
51. Lea AP, Faulds D. Stavudine: a review of its pharmacodynamic and pharmacokinetic properties and clinical potential in HIV infection. Drugs 1996;51:846-64
52. Havlir DV, Gilbert PB, Bennett K, et al. Effects of treatment intensification with hydroxycarbamide in HIV-infected patients with virologic suppression. AIDS 2001;15:1379-88
53. Reisler RB, Murphy RL, Redfield RR, Parker RA. Incidence of pancreatitis in HIV-1-infected individuals enrolled in 20 adult AIDS clinical trials group studies: lessons learned. J Acquir Immune Defic Syndr 2005;39:159-66
54. Gisolf EH, Dreezen C, Danner SA, et al. Risk factors for hepatotoxicity in HIV-1-infected patients receiving ritonavir and saquinavir with or without stavudine. Prometheus Study Group. Clin Infect Dis 2000;31:1234-9
55. Anderson PL, Kakuda TN, Lichtenstein KA. The cellular pharmacology of nucleoside- and nucleotide-analogue reverse-transcriptase inhibitors and its relationship to clinical toxicities. Clin Infect Dis 2004;38:743-53
56. Falco V, Rodriguez D, Ribera E, et al. Severe nucleoside-associated lactic acidosis in human immunodeficiency virus-infected patients: report of 12 cases and review of the literature. Clin Infect Dis 2002;34:838-46
57. Grinspoon S, Carr A. Cardiovascular risk and body-fat abnormalities in HIV-infected adults. N Engl J Med 2005;352:48-62
58. Brown TT, Li X, Cole SR, et al. Cumulative exposure to nucleoside analogue reverse transcriptase inhibitors is associated with insulin resistance markers in the Multicenter AIDS Cohort Study. AIDS 2005;19:1375-83
59. Mutimura E, Stewart A, Rheeder P, Crowther NJ. Metabolic function and the prevalence of lipodystrophy in a population of HIV-infected African subjects receiving highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2007;46:451-5
60. Mandelbrot L, Kermarrec N, Marcollet A, et al. Case report: nucleoside analogue-induced lactic acidosis in the third trimester of pregnancy. AIDS 2003;17:272-3
61. Sarner L, Fakoya A. Acute onset lactic acidosis and pancreatitis in the third trimester of pregnancy in HIV-1 positive women taking antiretroviral medication. Sex Transm Infect 2002;78:58-9
62. Jamisse L, Balkus J, Hitti J, et al. Antiretroviral-associated toxicity among HIV-1-seropositive pregnant women in Mozambique receiving nevirapine-based regimens. J Acquir Immune Defic Syndr 2007;44:371-6
63. Grey G, Violari A, McIntyre J, et al. Antiviral activity of nucleoside analogues during short-course monotherapy or dual therapy: its role in preventing HIV infection in infants. J Acquir Immune Defic Syndr 2006;42:169-76
64. Addendum to 2006 WHO guidelines on antiretroviral therapy for HIV infection in adults and adolescents. New dosage recommendations for stavudine (d4T). Geneva, Switzerland: World Health Organization, 2007. Available from: www.who.int/hiv/art/ARTadultsaddendum.pdf [Last accessed 11 January 2008]
65. El-Sadr WM, Lundgren JD, Neaton JD, et al. CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med 2006;355:2283-96
66. Danel C, Moh R, Minga A, et al. CD4-guided structured antiretroviral treatment interruption strategy in HIV-infected adults in west Africa (Trivacan ANRS 1269 trial): a randomized trial. Lancet 2006;367:1981-9
67. Arnedo-Valero M, Garcia F, Gil C, et al. Risk of selecting de novo drug resistance mutations during structured treatment interruptions in patients with chronic HIV infection. Clin Infect Dis 2005;41:883-90
68. Petersen EA, Ramirez-Ronda CH, Hardy WD, et al. Dose-related activity of stavudine in patients infected with human immunodeficiency virus. J Infect Dis 1995;171(Suppl 2):S131-9
69. Simpson DM, Tagliati M. Nucleoside analogue-associated peripheral neuropathy in human immunodeficiency virus infection. J Acquir Immune Defic Syndr Hum Retrovirol 1995;9:153-61
70. Carr A, Workman C, Smith DE, et al. Abacavir substitution for nucleoside analogs in patients with HIV lipoatrophy: a randomized trial. JAMA 2002;288:207-15
71. Lonergan JT, McComsey GA, Fisher RL, et al. Lack of recurrence of hyperlactatemia in HIV-infected patients switched from stavudine to abacavir or zidovudine. J Acquir Immune Defic Syndr 2004;36:935-42
72. Harris M CH, Bruce S, Chan J, et al. Impact on mitochondrial toxicity and antiviral effect of switching from stavudine (d4t) to tenofovir df [abstract 730]. Antivir Ther 2003;8(Suppl 1)
73. Llibre JM, Domingo P, Palacios R, et al. Sustained improvement of dyslipidaemia in HAART-treated patients replacing stavudine with tenofovir. AIDS 2006;20:1407-14
74. 3. J Acquir Immune Defic Syndr 1999;22:39-48
75. Anderson RE, Dunkle LM, Smaldone L, et al. Design and implementation of the stavudine parallel-track program. J Infect Dis 1995;171(Suppl 2):S118-22
76. Shalit P, Farrell P, McClarty M. Long-term efficacy of a protease inhibitor-sparing, nucleoside reverse transcriptase inhibitor-limiting antiretroviral regimen with nevirapine, lamivudine, and reduced standard stavudine dosage. HIV Clin Trials 2004;5:62-4
77. Hill A, Ruxrungtham K, Hanvanich M, et al. Systematic review of clinical trials evaluating low doses of stavudine as part of antiretroviral treatment. Expert Opin Pharmacother 2007;8:679-88
78. Sanchez-Conde M, Soriano V, Gonzalez-Lahoz J. Dose reduction in stavudine from 40 mg to 30 mg b.i.d. provides similar virological and immunological outcome. XV International AIDS Conference; 2004 Jul 11 - 16; Bangkok, Thailand Abstract TuPeB4459
79. Milinkovic A, Lopez S, Vidal S, et al. A randomized open study comparing the effect of reducing stavudine dose vs switching to tenofovir on mitochondrial function, metabolic parameters, and subcutaneous fat in HIV-infected patients receiving antiretroviral therapy containing stavudine. 12th Conference on Retroviruses and Opportunistic Infections, 2005 Feb 22 - 25; Boston, USA (paper 857)
80. Max B, Sherer R. Management of the adverse effects of antiretroviral therapy and medication adherence. Clin Infect Dis 2000;30(Suppl 2):S96-116
81. van Oosterhout JJ, Bodasing N, Kumwenda JJ, et al. Evaluation of antiretroviral therapy results in a resource-poor setting in Blantyre, Malawi. Trop Med Int Health 2005;10:464-70
82. Thoni GJ, Fedou C, Brun JF, et al. Reduction of fat accumulation and lipid disorders by individualized light aerobic training in human immunodeficiency virus infected patients with lipodystrophy and/or dyslipidemia. Diabetes Metab 2002;28:397-404
83. McComsey GA, O'Riordan M, Setzer B, et al. Uridine supplementation in HIV lipoatrophy: pilot trial on safety and effect on mitochondrial indices. Eur J Clin Nutr 2007 [Epub ahead of print]
84. Sutinen J, Walker UA, Sevastianova K, et al. Uridine supplementation for the treatment of antiretroviral therapy-associated lipoatrophy: a randomized, double-blind, placebo-controlled trial. Antivir Ther 2007;12:97-105
85. Backonja M, Glanzman RL. Gabapentin dosing for neuropathic pain: evidence from randomized, placebo-controlled clinical trials. Clin Ther 2003;25:81-104
86. Sungkanuparph S, Manosuthi W, Kiertiburanakul S, et al. Options for a second-line antiretroviral regimen for HIV type 1-infected patients whose initial regimen of a fixed-dose combination of stavudine, lamivudine, and nevirapine fails. Clin Infect Dis 2007;44:447-52
87. Kempf DJ, King MS, Bernstein B, et al. Incidence of resistance in a double-blind study comparing lopinavir/ritonavir plus stavudine and lamivudine to nelfinavir plus stavudine and lamivudine. J Infect Dis 2004;189:51-60
88. Berhane K, Karim R, Cohen MH, et al. Impact of highly active antiretroviral therapy on anemia and relationship between anemia and survival in a large cohort of HIV-infected women: Women's Interagency HIV Study. J Acquir Immune Defic Syndr 2004;37:1245-52
89. Grasela DM, Stoltz RR, Barry M, et al. Pharmacokinetics of single-dose oral stavudine in subjects with renal impairment and in subjects requiring hemodialysis. Antimicrob Agents Chemother 2000;44:2149-53